Quantcast

Latest Diabetes management Stories

2014-06-16 16:25:39

Phase 3 Study Results Also Demonstrate INVOKANA® Reduces Secondary Endpoints of Body Weight and Systolic Blood Pressure RARITAN, N.J., June 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term effects of INVOKANA(®) (canagliflozin) in patients aged 55 to 80 years with type 2 diabetes inadequately controlled on current antihyperglycemic therapies. The randomized double-blind...

2014-06-16 12:58:06

Merck Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions....

2014-06-16 12:29:24

-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on to metformin RIDGEFIELD, Conn. and INDIANAPOLIS, June 16, 2014 /PRNewswire/ -- Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) were presented today at the American Diabetes Association 74th Scientific Sessions®,...

Diabetes Patients May Get Better Results With Bionic Pancreas
2014-06-16 10:23:47

Brett Smith for redOrbit.com - Your Universe Online A team of Massachusetts researchers working on a bionic pancreas were able to show that their device could maintain blood glucose levels consistently within the normal range, with fewer dangerous lows or highs, according to a paper published in the New England Journal of Medicine. The team said their device could make a massive difference in the lives of countless individuals coping with Type 1 diabetes. Conventional care for this kind...

2014-06-16 08:28:47

Algorithm in Development Maintained Glucose Above Hypoglycemic Levels Over 99% of Time in Feasibility Study CHESTERBROOK, Pa., June 16, 2014 /PRNewswire/ -- Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development. Data from a clinical feasibility study demonstrated that the algorithm was capable of helping maintain glucose above hypoglycemic levels an average of 99.1 percent of the time for the 12 participants investigated, all...

2014-06-16 08:27:42

Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGR(Rx) in addition to metformin achieved absolute mean reduction in hemoglobin...

2014-06-15 16:20:33

CONSISTENT 1 Trial Results Presented in Late-Breaker Poster SAN DIEGO, June 15, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco. The CONSISTENT 1 trial is evaluating Hylenex(®) recombinant and a new formulation of Hylenex currently under U.S. Food and Drug Administration (FDA) review, when used as...

2014-06-15 16:20:24

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs. empagliflozin or linagliptin alone after 24 weeks RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 /PRNewswire/ -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly...

2014-06-15 15:18:02

The Endocrine Society Study suggests metformin controls blood sugar more effectively in African-Americans African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). An estimated 29 million Americans have diabetes. African Americans are twice as likely to...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...


Latest Diabetes management Reference Libraries

Diabetes Care
2012-05-12 21:41:27

Diabetes Care is a peer-reviewed medical journal established in 1978 and published monthly by the American Diabetes Association. It covers research in the following five categories: clinical care/education/nutrition/psychosocial research; epidemiology/health services research; emerging treatments and technologies; pathophysiology/complications; and cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries....

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related